A clinical trial to assess biomarker modulation by tamoxifen in normal and premalignant breast tissue

Richard M Elledge, G. Clark, S. Mohsin, Pamela M Otto, T. Cruz, H. Chew, C. K. Osborne, D. C. Allred

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Prevention trials using incidence or mortality as endpoints require a large number of subjects and long followup. Trials using biomarkers as endpoints would potentially require less subjects, time and resources to test promising new agents for breast cancer prevention. To further test this idea, a randomized trial of tamoxifen for 1 year versus observation was conducted to determine whether tamoxifen can cause regression of hyperplastic breast tissue, whether it changes the biomarker phenotype of premalignant disease or normal breast epithelium, and if biomarkers can be used as early surrogate indicators of response to a prevention regimen. Women were identified by having an abnormal mammogram and a core needle or excisional biopsy with typical or atypical ductal hyperplasia. Image-directed core needle biopsy was repeated in the same site of the breast at one year. Approximately 3,000 patients were screened, 265 were eligible, and 230 were contacted. Sixty-three patients were randomized and 45 paired biopsies were available for analysis. Ethnicity reflected that of the community, with 65% of patients being Hispanic, 30% white, and 5% black. There was no evidence of substantial regression of hyperplasia - fewer samples showed hyperplasia on one-year follow-up, but this was seen in both untreated and tamoxifen-treated women. ER and PgR were relatively decreased and bcl-2 relatively increased in normal and hyperplastic tissue in the tamoxifen-treated arm, though these changes did not reach statistical significance. Conclusion: Prolonged tamoxifen appeared to down-regulate ER and PgR and up-regulate bcl-2 in both normal and hyperplastic breast tissue. Additional biomarker analysis is ongoing.

Original languageEnglish (US)
Pages (from-to)224
Number of pages1
JournalBreast Cancer Research and Treatment
Volume69
Issue number3
StatePublished - 2001
Externally publishedYes

Fingerprint

Tamoxifen
Breast
Biomarkers
Clinical Trials
Hyperplasia
Large-Core Needle Biopsy
Biopsy
Carcinoma, Intraductal, Noninfiltrating
Hispanic Americans
Needles
Arm
Up-Regulation
Down-Regulation
Epithelium
Observation
Breast Neoplasms
Phenotype
Mortality
Incidence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Elledge, R. M., Clark, G., Mohsin, S., Otto, P. M., Cruz, T., Chew, H., ... Allred, D. C. (2001). A clinical trial to assess biomarker modulation by tamoxifen in normal and premalignant breast tissue. Breast Cancer Research and Treatment, 69(3), 224.

A clinical trial to assess biomarker modulation by tamoxifen in normal and premalignant breast tissue. / Elledge, Richard M; Clark, G.; Mohsin, S.; Otto, Pamela M; Cruz, T.; Chew, H.; Osborne, C. K.; Allred, D. C.

In: Breast Cancer Research and Treatment, Vol. 69, No. 3, 2001, p. 224.

Research output: Contribution to journalArticle

Elledge, RM, Clark, G, Mohsin, S, Otto, PM, Cruz, T, Chew, H, Osborne, CK & Allred, DC 2001, 'A clinical trial to assess biomarker modulation by tamoxifen in normal and premalignant breast tissue', Breast Cancer Research and Treatment, vol. 69, no. 3, pp. 224.
Elledge, Richard M ; Clark, G. ; Mohsin, S. ; Otto, Pamela M ; Cruz, T. ; Chew, H. ; Osborne, C. K. ; Allred, D. C. / A clinical trial to assess biomarker modulation by tamoxifen in normal and premalignant breast tissue. In: Breast Cancer Research and Treatment. 2001 ; Vol. 69, No. 3. pp. 224.
@article{7fe8d09327b149c0ab98de24d9bc856d,
title = "A clinical trial to assess biomarker modulation by tamoxifen in normal and premalignant breast tissue",
abstract = "Prevention trials using incidence or mortality as endpoints require a large number of subjects and long followup. Trials using biomarkers as endpoints would potentially require less subjects, time and resources to test promising new agents for breast cancer prevention. To further test this idea, a randomized trial of tamoxifen for 1 year versus observation was conducted to determine whether tamoxifen can cause regression of hyperplastic breast tissue, whether it changes the biomarker phenotype of premalignant disease or normal breast epithelium, and if biomarkers can be used as early surrogate indicators of response to a prevention regimen. Women were identified by having an abnormal mammogram and a core needle or excisional biopsy with typical or atypical ductal hyperplasia. Image-directed core needle biopsy was repeated in the same site of the breast at one year. Approximately 3,000 patients were screened, 265 were eligible, and 230 were contacted. Sixty-three patients were randomized and 45 paired biopsies were available for analysis. Ethnicity reflected that of the community, with 65{\%} of patients being Hispanic, 30{\%} white, and 5{\%} black. There was no evidence of substantial regression of hyperplasia - fewer samples showed hyperplasia on one-year follow-up, but this was seen in both untreated and tamoxifen-treated women. ER and PgR were relatively decreased and bcl-2 relatively increased in normal and hyperplastic tissue in the tamoxifen-treated arm, though these changes did not reach statistical significance. Conclusion: Prolonged tamoxifen appeared to down-regulate ER and PgR and up-regulate bcl-2 in both normal and hyperplastic breast tissue. Additional biomarker analysis is ongoing.",
author = "Elledge, {Richard M} and G. Clark and S. Mohsin and Otto, {Pamela M} and T. Cruz and H. Chew and Osborne, {C. K.} and Allred, {D. C.}",
year = "2001",
language = "English (US)",
volume = "69",
pages = "224",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - A clinical trial to assess biomarker modulation by tamoxifen in normal and premalignant breast tissue

AU - Elledge, Richard M

AU - Clark, G.

AU - Mohsin, S.

AU - Otto, Pamela M

AU - Cruz, T.

AU - Chew, H.

AU - Osborne, C. K.

AU - Allred, D. C.

PY - 2001

Y1 - 2001

N2 - Prevention trials using incidence or mortality as endpoints require a large number of subjects and long followup. Trials using biomarkers as endpoints would potentially require less subjects, time and resources to test promising new agents for breast cancer prevention. To further test this idea, a randomized trial of tamoxifen for 1 year versus observation was conducted to determine whether tamoxifen can cause regression of hyperplastic breast tissue, whether it changes the biomarker phenotype of premalignant disease or normal breast epithelium, and if biomarkers can be used as early surrogate indicators of response to a prevention regimen. Women were identified by having an abnormal mammogram and a core needle or excisional biopsy with typical or atypical ductal hyperplasia. Image-directed core needle biopsy was repeated in the same site of the breast at one year. Approximately 3,000 patients were screened, 265 were eligible, and 230 were contacted. Sixty-three patients were randomized and 45 paired biopsies were available for analysis. Ethnicity reflected that of the community, with 65% of patients being Hispanic, 30% white, and 5% black. There was no evidence of substantial regression of hyperplasia - fewer samples showed hyperplasia on one-year follow-up, but this was seen in both untreated and tamoxifen-treated women. ER and PgR were relatively decreased and bcl-2 relatively increased in normal and hyperplastic tissue in the tamoxifen-treated arm, though these changes did not reach statistical significance. Conclusion: Prolonged tamoxifen appeared to down-regulate ER and PgR and up-regulate bcl-2 in both normal and hyperplastic breast tissue. Additional biomarker analysis is ongoing.

AB - Prevention trials using incidence or mortality as endpoints require a large number of subjects and long followup. Trials using biomarkers as endpoints would potentially require less subjects, time and resources to test promising new agents for breast cancer prevention. To further test this idea, a randomized trial of tamoxifen for 1 year versus observation was conducted to determine whether tamoxifen can cause regression of hyperplastic breast tissue, whether it changes the biomarker phenotype of premalignant disease or normal breast epithelium, and if biomarkers can be used as early surrogate indicators of response to a prevention regimen. Women were identified by having an abnormal mammogram and a core needle or excisional biopsy with typical or atypical ductal hyperplasia. Image-directed core needle biopsy was repeated in the same site of the breast at one year. Approximately 3,000 patients were screened, 265 were eligible, and 230 were contacted. Sixty-three patients were randomized and 45 paired biopsies were available for analysis. Ethnicity reflected that of the community, with 65% of patients being Hispanic, 30% white, and 5% black. There was no evidence of substantial regression of hyperplasia - fewer samples showed hyperplasia on one-year follow-up, but this was seen in both untreated and tamoxifen-treated women. ER and PgR were relatively decreased and bcl-2 relatively increased in normal and hyperplastic tissue in the tamoxifen-treated arm, though these changes did not reach statistical significance. Conclusion: Prolonged tamoxifen appeared to down-regulate ER and PgR and up-regulate bcl-2 in both normal and hyperplastic breast tissue. Additional biomarker analysis is ongoing.

UR - http://www.scopus.com/inward/record.url?scp=11144226598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144226598&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:11144226598

VL - 69

SP - 224

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -